WallStSmart

Churchill Capital Corp XI (CCXI)vsHCM II Acquisition Corp. Unit (HONDU)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HONDU leads profitability with a 0.0% profit margin vs 0.0%. CCXI earns a higher WallStSmart Score of 24/100 (F).

CCXI

Avoid

24

out of 100

Grade: F

Growth: 4.3Profit: 4.0Value: 5.0Quality: 6.0
Piotroski: 2/9

HONDU

Avoid

18

out of 100

Grade: F

Growth: 4.3Profit: 4.0Value: 5.0Quality: 4.0
Piotroski: 2/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCXI0 strengths · Avg: 0/10

No standout strengths identified

HONDU0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CCXI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$805.98M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

HONDU4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$525.00M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CCXI

CCXI has a balanced fundamental profile.

Bull Case : HONDU

HONDU has a balanced fundamental profile.

Bear Case : CCXI

The primary concerns for CCXI are Revenue Growth, EPS Growth, Market Cap.

Bear Case : HONDU

The primary concerns for HONDU are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

HONDU is growing revenue faster at 0.0% — sustainability is the question.

CCXI generates stronger free cash flow (-326,107), providing more financial flexibility.

Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CCXI scores higher overall (24/100 vs 18/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Churchill Capital Corp XI

FINANCIAL SERVICES · SHELL COMPANIES · USA

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.

HCM II Acquisition Corp. Unit

FINANCIAL SERVICES · SHELL COMPANIES · USA

HCM II Acquisition Corp. is a strategically focused special purpose acquisition company (SPAC) aimed at merging with high-growth enterprises within the healthcare sector. Backed by a seasoned management team with substantial industry expertise, HCM II is well-equipped to identify and capitalize on promising trends and innovations in healthcare. The firm offers institutional investors a unique opportunity to access transformative healthcare investments, driving potential value creation and fostering sustainable long-term returns in an increasingly dynamic market.

Want to dig deeper into these stocks?